Jcog 9511
Web1 giu 2002 · Based on the results of the JCOG 9511 trial, irinotecan plus cisplatin is considered to be the reference chemotherapy arm for ED-SCLC in future trials in Japan [23]. Web1 giu 2004 · However, SCLC israrely cured, although the responserate has been improved and the survivaltime extended through the useof chemotherapy. Based on the resultsof JCOG 9511 and JCOG 9902-DI, a randomized trial comparing IPwith IPE administered every 3 weeksin patients with previously untreatedED-SCLC is now being performed …
Jcog 9511
Did you know?
Web20 giu 2007 · 7524 Introduction: J9511 demonstrated a significant survival benefit for Cis/CPT11 over Cis/VP16 in Japanese patients (pts) with E-SCLC (Noda, et al. NEJM … WebJapan clinical oncology group study (Jcog 9511). in 2002, the Japan Clinical oncology Group (JCoG) reported data from a phase iii trial (n = 154) demonstrating that the substitu-
Webcal Oncology Group (JCOG) 9511 trial demonstrated that cisplatin plus irinotecan (CPT-11) improved overall survival (OS) compared with a cisplatin plus etoposide regimen in … WebZestimate® Home Value: $679,900. 9211 95th St, Jamaica, NY is a single family home that contains 1,350 sq ft and was built in 1920. It contains 4 bedrooms and 1 bathroom. The …
WebAlthough the dose intensity for irinotecan and cisplatin in the SWOG S0104 trial (irinotecan 66%, cisplatin 78%) was lower than that of the JCOG 9511 trial (irinotecan 80%, cisplatin … WebJCOG trials (Noda et al, 2002). The data of JCOG 9511 are clearly interesting, however, only 154 patients have been randomised. It is essential to evaluate the reproducibility of the effect of CPT-11.
WebBecause of the small number of patients (n = 174), the study involved a solely Japanese population. Subsequently, a phase III trial by the Southwest Oncology Group (SWOG)-0124 was conducted to confirm the results of JCOG-9511 in 651 people from North America, with similar eligibility criteria to those in the Japanese trial .
WebJCoG 9511 study. Final results from the only european trial demonstrated a 1.4-month median survival improvement with irinotecan compared with etoposide (8.5 versus 7.1 … fix leaky toiletWeb20 giu 2007 · 7524 Introduction: J9511 demonstrated a significant survival benefit for Cis/CPT11 over Cis/VP16 in Japanese patients (pts) with E-SCLC (Noda, et al. NEJM 2002). S0124 is the confirmatory North American phase III trial (accrual completed) using the identical J9511 protocol. We hypothesized that toxicities would differ between North … fixleaningpastWeb17 mar 2014 · In 2002, a phase III trial conducted by the Japan Clinical Oncology Group (JCOG 9511) demonstrated the superiority of irinotecan plus cisplatin (IP) over EP for patients with ED-SCLC. 4 Median survival time (MST) and 1-year survival for the IP and EP arms were 12.8 versus 9.4 months and 58.4% versus 37.7%, respectively, but patients in … fix leather bag strapWeb1 mar 2024 · ALWAYS download the form to a location of your choice. Then open the form from that location. 4. Use MicroSoft Edge browser as much as possible instead of … fix leaning reclinerfix leaky showerWeb6 apr 2009 · Over the past two decades, the cornerstone of therapy for extensive-stage SCLC has been a platinum compound (either carboplatin or cisplatin) in combination with the topoisomerase-II inhibitor etoposide. 7 In 2002, a Japanese phase III study (Japan Clinical Oncology Group [JCOG] 9511) comparing etoposide plus cisplatin (EP) with … fix leaky spigotWeb1 giu 2002 · Based on the results of the JCOG 9511 trial, irinotecan plus cisplatin is considered to be the reference chemotherapy arm for ED-SCLC in future trials in Japan … fix leaky toilet stopper